Sarepta Therapeutics, Inc. (SRPT) SEC Filings & Earnings Calls

Litigation resolved with $39M cash payment, but covenant not to sue limits future challenges; previously accrued as contingency.

“recorded a litigation contingency charge of $39.0 million related to the anticipated settlement” · word for word

ELEVIDYS label restriction to ambulatory patients only

“In November 2025, we announced a boxed warning for ALI and ALF and removal of non-ambulatory population from the Indication and Usage section of the Prescribing Information for ELEVIDYS.” · word for word

ESSENCE trial failure may lead to regulatory action on PMO products

“The topline results did not show statistical significance on the study's primary endpoint.” · word for word

Clinical hold on LGMD gene therapy programs

“On July 21, 2025, we announced that the FDA placed a clinical hold on our investigational use gene therapy trials for LGMD... following the death of a patient in our Phase 1 LGMD clinical trial for SRP-9004.” · word for word

Manufacturing quality issues leading to batch write-offs

“increases in our manufacturing costs driven by greater-than-expected write-offs of batches of our products not meeting our quality specifications” · word for word

Patent litigation settlement risk

“we recorded a litigation contingency charge of $39.0 million related to the potential resolution of certain patent litigations.” · word for word

ELEVIDYS revenue decline due to label restriction to ambulatory patients only.

“Lower volume of ELEVIDYS sales due to our updated label that only includes the ambulatory patient population for treatment.” · word for word

GAAP net loss of $4.9M in Q2 2026 vs net income of $196.9M in prior year.

“Net (loss) income: GAAP $(4.9) million, Non-GAAP $78.6 million”

Leadership transition risk; new CEO may implement strategic changes.

“CEO change from Douglas Ingram to Dr. Michael Severino; consulting agreement for transition.”

High CEO compensation could impact shareholder dilution and expenses.

“$35M sign-on equity grant; significant compensation package.”

Potential dilution from new equity plans, though routine.

“New plans authorize issuance of up to 7.8M shares total.”

ELEVIDYS sales impacted by label restriction to ambulatory patients; potential for further regulatory or commercial challenges.

“This primarily reflects a lower volume of ELEVIDYS sales due to our updated label that only includes the ambulatory patient population for treatment.” · word for word

ELEVIDYS label restriction and safety events

“In November 2025, we announced a boxed warning for ALI and ALF and removal of non-ambulatory population from the Indication and Usage section of the Prescribing Information for ELEVIDYS.” · word for word

ESSENCE trial failure threatens PMO product approvals

“The topline results did not show statistical significance on the study's primary endpoint. We intend to discuss with FDA the potential pathway forward.” · word for word

Clinical hold on LGMD gene therapy trials

“On July 21, 2025, we announced that the FDA placed a clinical hold on our investigational use gene therapy trials for LGMD... following the death of a patient in our Phase 1 LGMD clinical trial for SRP-9004.” · word for word

Cash burn and milestone obligations

“Our principal uses of cash for the three months ended March 31, 2026 were our repayment of borrowings from the Revolving Credit Facility, the payment of $200.0 million for the second DM1 Milestone to Arrowhead, the $50.0 million annual license fee payment to Arrowhead.” · word for word

CEO Succession Risk

“In February 2026, Mr. Ingram announced his intention to retire by the end of 2026 or upon the appointment of his replacement.” · word for word

Product Safety Risk (ELEVIDYS)

“In June, we acted decisively to pause shipping of ELEVIDYS to non-ambulatory patients following two reported cases of acute liver failure resulting in death of non-ambulatory patients to evaluate these new safety signals.” · word for word

Clinical Trial Failure Risk (PMO)

“We received top-line results from ESSENCE, our confirmatory trial for two of our PMO products, AMONDYS 45 and VYONDYS 53. Although the study did not meet its primary endpoint.” · word for word

Financial Restatement Risk

“We identified an error in the financial statements included in our quarterly report on Form 10-Q for the quarterly period ended September 30, 2025 related to the accounting for our partial refinancing of our convertible senior notes due in 2027.” · word for word

Debt Refinancing Risk

“Our convertible debt exchanges in August and December 2025 reduced the total amount due under our outstanding convertible notes due in 2027 from $1.15 billion to $159 million.” · word for word

Gene therapy safety risk

“In March and June 2025, we announced two reported cases of ALF resulting in death in non-ambulatory patients following treatment with ELEVIDYS.” · word for word

Confirmatory trial failure

“On November 3, 2025, we announced topline results from our ESSENCE trial, a confirmatory trial intended to verify the clinical benefits of VYONDYS 53 and AMONDYS 45, which primary endpoint did not meet statistical significance.” · word for word

Drug pricing pressure from U.S. healthcare reform

“The Inflation Reduction Act ('IRA') of 2022 includes a number of changes intended to address rising prescription drug prices in Medicare Parts B and D, with varying implementation dates.” · word for word

Leadership transition risk during CEO search; potential strategic uncertainty.

“CEO retirement announcement; search for internal/external candidates.”

ELEVIDYS label changes and non-ambulatory indication removal may limit future market.

“Updated prescribing information added boxed warning for serious liver injury, removed non-ambulatory indication.”

Preliminary financials subject to adjustment; ELEVIDYS Q4 revenue impacted by flu season and rescheduled infusions.

“ELEVIDYS fourth quarter revenue was impacted by the severe year-end flu season and the need in December to reschedule 6 patient infusions into 2026.” · word for word

Higher coupon on new notes increases interest expense; potential dilution from conversion.

“4.875% Convertible Senior Notes due 2030 vs 1.25% previously; total $893.4M outstanding.” · word for word

Increased coupon and potential dilution from conversion.

“Coupon increases from 1.25% to 4.875%; convertible notes may be converted into common stock.”

Regulatory risk from ELEVIDYS suspension

“In response to safety events announced in March and June 2025, in June 2025, we suspended all shipments of ELEVIDYS to non-ambulatory patients in the U.S.” · word for word

Confirmatory trial failure for PMO products

“On November 3, 2025, we announced top-line results from our ESSENCE trial...The topline results did not show statistical significance on the study's primary endpoint.” · word for word

Liquidity risk from Arrowhead commitments

“The Arrowhead Agreement includes a commitment of $250.0 million in guaranteed payments to be paid in five equal annual installments of $50.0 million, beginning in February 2026.” · word for word

Clinical hold on LGMD gene therapy programs

“On July 21, 2025, we announced that the FDA placed a clinical hold on our investigational use gene therapy clinical trials for LGMD...following the death of a patient in our Phase 1/2 LGMD clinical trial for SRP-9004.” · word for word

ESSENCE primary endpoint miss could delay traditional approval; regulatory risk remains.

“ESSENCE did not achieve statistical significance on primary endpoint (P=0.309).”